Impact of Oral Dyglomera™ on Body Fat and Blood Lipids of Overweight and Obese Adults

Not Applicable

Completed

• Conditions: Body Fat Disorder
• Interventions: Dietary Supplement: Oral Dyglomera

• Registration Number: NCT05483192
• Lead Sponsor: Gateway Health Alliance

Brief Summary

The extract of Dichrostachys glomerata (DyglomeraTM), has been reported to be effective in weight reduction in obese patients with metabolic syndrome. This plant has been shown to have many biological properties and has been reported to have no toxic or adverse side effects in animals. The purpose of this human study was to prove that the effect of reducing body fat percentage (%) after 12 weeks of intake was superior to that of the control group.

Detailed Description

This is a 12-weeks randomized double-blind placebo controlled trial. 120 number of subjects are planned. Each subject will be administered a single dose of the investigational product once daily, before lunch or dinner, consisting each time of 400 mg of the test product or placebo. Subjects will be assigned to the test group or placebo group in random order. Evaluations will be taken at baseline and at the beginning of each of the 5 study visits.

Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.

The following investigational products will be used:

* Test product: Dichrostachys glomerata extract (Dyglomera™) at a dose of 400 mg

* Control product: Placebo at a dose of 400 mg In this human study, starting with Visit 2, the duration of participation in the human study will be 12 weeks (84 days) in total. The study period will be planned to be 8 months from the date of approval of the human study. The screening visit of the first subject will be conducted at the MAX SPECIALTY HOSPITAL, and the first subject will be enrolled thereafter. The last subject will complete the study within about 5 months.

Study Timeline

• Study Start: 2021-02-12
• Primary Completion: 2021-06-12
• Study Completion: 2021-06-18
• Status Verified: 2022-07
• Study First Submitted: 2022-07-19
• Study First Submitted QC: 2022-08-01
• Last Update Submitted: 2022-08-01
• Study First Posted: 2022-08-02
• Last Update Posted: 2022-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients aged from 19 to 65 years old,
• Patients with a BMI ranging between 25 and 34.9 kg/m2,
• Patients available for the entire period of study .

Exclusion Criteria

• Patients that has an age below 19 years old and greater than 65 years old,
• Patients not available for the study period,
• Specific exclusion criteria included: morbid obesity (BMI > 34.9 kg/m2); diabetes mellitus requiring daily insulin management; pregnancy/lactation; active infection; and systemic disease such as HIV/AIDS, active hepatitis or clinical signs of active malignancy within the past 5 years. Other exclusion criteria will include having taken any other medications or any natural health product within 1 month prior to the screening visit.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Comparison between placebo and active treatment	Oral Dyglomera	120 subjects were planned. Screening data was reviewed to determine subject eligibility. Subjects who met all inclusion criteria and none of the exclusion criteria were enrolled into the study. The following investigational products were used: * Test product: Dichrostachys glomerata extract (Dyglomera™) at a dose of 400 mg * Control product: Placebo at a dose of 400 mg Subjects were assigned to the test group or placebo group in random order. Each subject was administered a single 400 mg dose of Dyglomera or placebo once daily, before lunch or dinner. Measurements were taken at baseline and at the beginning of each of the 5 study visits.
Comparison of baseline to final outcome	Oral Dyglomera	The effect of Dyglomera on body fat and blood parameters were compared at baseline and at the end of the intervention period.

Primary Outcome Measures

Name	Time	Method
Effect of Dyglomera on body fat of overweight and obese people	12 weeks	DEXA and impedance measurement of body fat

Secondary Outcome Measures

Name	Time	Method
Effect of Dyglomera on HDL-cholesterol levels of overweight and obese people	12 weeks	Blood assay to measure HDL-cholesterol
Effect of Dyglomera on CRP levels of overweight and obese people	12 weeks	Blood assay to measure CRP
Effect of Dyglomera on leptin levels of overweight and obese people	12 weeks	Blood assay to measure leptin
Effect of Dyglomera on blood insulin levels of overweight and obese people	12 weeks	Blood assay to measure insulin
Effect of Dyglomera on ALT levels of overweight and obese people	12 weeks	Blood assay to measure ALT
Effect of Dyglomera on blood triglyceride levels of overweight and obese people	12 weeks	Blood assay to measure blood total triglycerides
Effect of Dyglomera on fasting blood glucose levels	12 weeks	Blood assay to measure fasting blood glucose
Effect of Dyglomera on adiponectin levels of overweight and obese people	12 weeks	Blood assay to measure blood adiponectin
Effect of Dyglomera on blood cholesterol levels of overweight and obese people	12 weeks	Blood assay to measure blood total cholesterol
Effect of Dyglomera on AST levels of overweight and obese people	12 weeks	Blood assay to measure blood AST

Trial Locations

Locations (1)

Max Super Specialty Hospital; 🇮🇳 New Delhi, Patparganj, India